Posters

Long-term efficacy and safety of photodynamic therapy on central serous chorioretinopathy

Poster Details

First Author: Y.Park SOUTH KOREA

Co Author(s):    S. Woo   Y. Kim   K. Park                       

Abstract Details



Purpose:

To investigate long-term efficacy and safety of photodynamic therapy(PDT) on central serous chorioretinopathy(CSCR)

Setting:

Retrospective single-centre case series

Methods:

Patients who were treated with verteporfin PDT for CSCR in Seoul National University Bundang Hospital between March 2005 and March 2017 with a minimum follow-up of 36 months were reviewed. Patients previously treated with anti-VEGF injection for CSCR or having history of other chorioretinal disorders including choroidal neovascularization were excluded. Best-corrected visual acuities, central foveal thickness, subfoveal choroidal thickness, and photoreceptor recovery status were collected. Cox proportional hazard model was used for identifying risk factors for recurrence.

Results:

A total of 77 eyes of 74 patients were included. The mean age was 47.9 ± 7.3 (32.6 – 76.6) years and the mean follow-up duration was 57.3 ± 19.1 (36.1 – 129.3) months. 6 eyes(7.8%) underwent standard fluence PDT with standard dose, whereas 59 eyes underwent half-fluence PDT(76.7%) and 12 eyes (15.6%)underwent half-dose PDT. The mean visual improvement at the last follow-up was -0.17 ± 0.33 (-1.7 - 0.9, logMAR). In 6 eyes (7.8%), subretinal fluid was persistent until last follow-up date or until secondary treatment including re-PDT and anti-VEGF injection was done. In 14 eyes (18.2%), recurrence of subretinal fluid was detected. Cox regression analysis revealed no significant factor in reducing the risk of persistence and recurrence of subretinal fluid after PDT. 3 eyes(3.9%) developed choroidal neovascularization after PDT.

Conclusions:

Verteporfin PDT for the treatment of CSCR showed good efficacy. Further study is needed for choroidal neovascularization after PDT, comparing the incidence with untreated controls.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy